ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.65%. A quarter ago, it was expected that this immunotherapy company would post a loss of $0.16 per share when it actually produced a loss of $0.20, delivering a surprise of -25%. Over the last four quarters, the company h ...